TELA Bio, Inc. (NASDAQ:TELA – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $2.14.
Several equities research analysts have recently weighed in on the company. Craig Hallum assumed coverage on TELA Bio in a research report on Friday, September 25th. They set a “buy” rating and a $2.00 price target on the stock. Weiss Ratings lowered shares of TELA Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 9th. Finally, UBS Group set a $2.00 price objective on shares of TELA Bio in a research report on Friday, September 25th.
Read Our Latest Research Report on TELA Bio
TELA Bio Stock Performance
Shares of NASDAQ TELA opened at $0.97 on Tuesday. TELA Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.56. The stock has a market cap of $43.80 million, a PE ratio of -1.26 and a beta of 1.36. The stock has a fifty day moving average of $0.96 and a 200-day moving average of $0.85.
TELA Bio (NASDAQ:TELA – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 51.53%. The company had revenue of $19.29 million for the quarter, compared to analysts’ expectations of $20.01 million. On average, sell-side analysts predict that TELA Bio will post -0.76 EPS for the current year.
Insider Transactions at TELA Bio
In other news, Director Joseph Capper purchased 25,000 shares of the business’s stock in a transaction on Thursday, September 17th. The stock was purchased at an average cost of $1.22 per share, with a total value of $30,500.00. Following the acquisition, the director directly owned 179,827 shares in the company, valued at approximately $219,388.94. This trade represents a 16.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have purchased 115,000 shares of company stock valued at $119,500. Corporate insiders own 1.10% of the company’s stock.
Institutional Trading of TELA Bio
Several institutional investors and hedge funds have recently made changes to their positions in TELA. UP Strategic Wealth Investment Advisors LLC purchased a new position in shares of TELA Bio during the 2nd quarter valued at about $91,000. BlackRock Inc. purchased a new stake in TELA Bio in the second quarter worth approximately $281,000. Perkins Capital Management Inc. grew its position in TELA Bio by 1.5% during the first quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company’s stock valued at $879,000 after acquiring an additional 20,910 shares during the last quarter. Stonepine Capital Management LLC bought a new position in TELA Bio during the second quarter valued at approximately $1,996,820. Finally, Nantahala Capital Management LLC bought a new position in TELA Bio during the second quarter valued at approximately $4,420,586. Hedge funds and other institutional investors own 94.35% of the company’s stock.
About TELA Bio
TELA Bio, Inc is a medical technology company focused on developing and commercializing devices for soft-tissue reconstruction. Its products are designed to reinforce and repair damaged or weakened tissue while supporting the body’s natural healing processes.
The company’s portfolio is centered on its OviTex Reinforced Tissue Matrix products, which combine biologic tissue with a polymer reinforcement structure. OviTex products are used in a range of surgical applications, including abdominal wall reconstruction, hernia repair, breast reconstruction, and other soft-tissue repair procedures.
Featured Stories
- Five stocks we like better than TELA Bio
- Amprius Technologies’ Next Big Rally Could Be Taking Shape
- 4 Stocks With Demand So Sticky That the AI Sell-Off Barely Touched Them at All
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.
